Arrowhead Gold to Sign Definitive Agreement to Acquire Bio Therapeutic Molecules Inc.
June 18, 2015 at 09:51 AM EDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 18, 2015) - Arrowhead Gold Corp. (the "Company") (CSE:AWH) is pleased to announce, as per its news release of March 15, 2015, that it is moving forward with a definitive agreement to acquire 100% of the outstanding shares of Bio Therapeutic Molecules Inc. ("BTMI"), a private company, with its headquarters in Guelph, Ontario.
Pursuant to the Agreement, Arrowhead will acquire all shares of BTMI from the BTMI shareholders in exchange for 41.5 million common shares of Arrowhead.
Closing is contingent upon completion of a financing and to have a minimum $2.0 million on deposit after closing. Management of AWH are required to enter into a voting support agreement pursuant to which they will vote their shares of AWH in support of the transactions set out in the LOI.
BTMI will nominate candidates for election to AWH's Board of Directors.
AWH will obtain all applicable regulatory and shareholder approvals.
Bio Therapeutic Molecules Inc.
BTMI has a multi-disciplinary scientific team of principals and advisors who are experts in horticultural science, including metabolism, biochemistry, physiology, breeding and production, as well as the pharmaceutical industry, including discovery, development, manufacturing and marketing of drugs.
BTMI has developed a two-platform business model:
- Generating immediate cash flow (with growth potential) in Product Development and Research Management (PDRM) services. PDRM services will include: Opportunity Assessment (Market Analysis, Due Diligence); CMC (Chemistry, Manufacturing and Controls) Management; Project Management; and, Clinical and Pre-Clinical Toxicology.
Cash flow from these services will be used to develop an equity stake in a portfolio of "Active Pharmaceutical Ingredient" (API) and drug products with long-term value potential.
- BTMI has submitted an application to Health Canada to become a Licensed Producer of Medical Marihuana. Direct sale of dried marihuana against current regulation will support near term growth, and discovery activities with respect to phyto/bio-active molecules will be pursued to establish a pipeline of potential products for longer term growth.
Cash flow from sale of medicinal marihuana will be used to auto finance R&D into Cannabis-based pharmaceutical products.
On Behalf of the Board of Arrowhead Gold Corp.,
Steve Smith, President
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. There is no assurance the private placement referred to above will close on the terms as stated, or at all. The Company disclaims any intention or obligation to revise or update such statements.
Arrowhead Gold Corp.